Aurobindo Pharma Limited has announced a major share buyback program, with the Board approving the repurchase of up to 5,423,728 equity shares. This initiative, valued at an aggregate of INR 800 crore, will be executed through the tender offer route. The buyback is priced at INR 1,475 per share, reflecting the company’s commitment to returning value to shareholders. The record date for determining eligible participants has been set for April 17, 2026.
Buyback Details and Pricing
The Board of Directors of Aurobindo Pharma has authorized a buyback program to repurchase up to 5,423,728 equity shares, which represents 0.93% of the total paid-up equity capital. The buyback will be conducted at a price of INR 1,475 per share. The total outlay for this corporate action is capped at INR 800 crore, excluding transaction costs, taxes, and other related expenses.
Shareholder Participation and Timeline
The share repurchase will be carried out on a proportionate basis via the tender offer route, involving both public shareholders and members of the promoter group. The company has designated April 17, 2026, as the Record Date to identify shareholders eligible to participate in the buyback. A specialized Buyback Committee has been constituted to oversee the execution, manage the process, and handle all operational requirements associated with the transaction.
Strategic Context
This buyback represents approximately 3.93% and 2.62% of the company’s total paid-up equity share capital and free reserves, based on the latest audited financial statements as of March 31, 2025. While the pre-buyback shareholding reflects a significant 51.82% stake held by the Promoters and Promoter Group, the final post-buyback structure will be determined once the actual number of shares tendered and accepted is confirmed after the record date.
Source: BSE
